Regulus Therapeutics Inc.

NAS: RGLS

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Regulus Therapeutics Inc.

After Hours

--Quotes are delayed by 20 min

Dec 7, 2023, 7:29 p.m.

RGLS

/zigman2/quotes/202916513/composite

1.20

Change

-0.24 -16.42%

Volume

Volume 13

Quotes are delayed by 20 min

/zigman2/quotes/202916513/composite

Previous close

$ 1.39

$ 1.44

Change

+0.05 +3.29%

Day low

Day high

$1.37

$1.46

52 week low

52 week high

$0.76

$2.14

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Regulus Therapeutics Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	72,000	6.83M	10.01M	-	-
Sales Growth	-	9,388.89%	46.46%	-	-
Cost of Goods Sold (COGS) incl. D&A	-	-	-	459,000	122,000
COGS excluding D&A	-	-	-	-	-
Depreciation & Amortization Expense	2.26M	931,000	467,000	459,000	122,000
Depreciation	2.16M	900,000	367,000	359,000	96,000
Amortization of Intangibles	100,000	31,000	100,000	100,000	26,000
COGS Growth	-	-	-	-	-73.42%
Gross Income	-	-	-	(459,000)	(122,000)
Gross Income Growth	-	-	-	-	73.42%
Gross Profit Margin	-	-	-	-	-	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	43.77M	22.74M	23.69M	27.36M	28.12M
Research & Development	33.1M	11.78M	14.9M	17.35M	18.31M
Other SG&A	10.67M	10.96M	8.8M	10.01M	9.8M
SGA Growth	-	-48.06%	4.22%	15.46%	2.78%
Other Operating Expense	-	-	-	-	-
Unusual Expense	800,000	-	-	-	-
EBIT after Unusual Expense	(46.76M)	-	-	-	-
Non Operating Income/Expense	-	-	-	-	-
Non-Operating Interest Income	459,000	374,000	233,000	864,000	605,000
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	2.34M	2.13M	1.81M	855,000	688,000
Interest Expense Growth	-	-9.05%	-15.16%	-52.71%	-19.53%
Gross Interest Expense	2.34M	2.13M	1.81M	855,000	688,000
Interest Capitalized	-	-	-	-	-
Pretax Income	(48.65M)	(18.59M)	(15.73M)	(27.81M)	(28.32M)
Pretax Income Growth	-	61.78%	15.39%	-76.78%	-1.85%
Pretax Margin	-	-	-	-	-	NA
Income Tax	62,000	1,000	-	1,000	1,000
Income Tax - Current Domestic	(25,000)	(12,000)	(12,000)	1,000	1,000
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	87,000	13,000	12,000	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(48.71M)	(18.59M)	(15.73M)	(27.81M)	(28.32M)
Minority Interest Expense	-	-	-	-	-
Net Income	(48.71M)	(18.59M)	(15.73M)	(27.81M)	(28.32M)
Net Income Growth	-	61.83%	15.39%	-76.78%	-1.85%
Net Margin Growth	-	-	-	-	-	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(48.71M)	(18.59M)	(15.73M)	(27.81M)	(28.32M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(48.71M)	(18.59M)	(15.73M)	(27.81M)	(28.32M)
EPS (Basic)	(55.87)	(10.77)	(4.50)	(3.24)	(1.86)
EPS (Basic) Growth	-	80.72%	58.25%	27.85%	42.80%
Basic Shares Outstanding	871,856	1.73M	3.5M	8.57M	15.26M
EPS (Diluted)	(55.87)	(10.77)	(4.50)	(3.24)	(1.86)
EPS (Diluted) Growth	-	80.72%	58.25%	27.85%	42.80%
Diluted Shares Outstanding	871,856	1.73M	3.5M	8.57M	15.26M
EBITDA	(43.7M)	(15.9M)	(13.69M)	(27.36M)	(28.12M)
EBITDA Growth	-	63.61%	13.93%	-99.86%	-2.78%
EBITDA Margin	-	-	-	-	-	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Regulus Therapeutics Inc.

Annual Financials for Regulus Therapeutics Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk